Analysis of CD137L and IL-17 Expression in Tumor Tissue as Prognostic Indicators for Gliblastoma
Open Access
- 1 January 2013
- journal article
- Published by Ivyspring International Publisher in International Journal of Biological Sciences
- Vol. 9 (2), 134-141
- https://doi.org/10.7150/ijbs.4891
Abstract
Glioblastoma multiforme (GBM) is the most common form of malignant glioma, characterized by genetic instability and unpredictable clinical behavior. GBM is marked by an extremely poor prognosis with median overall survival of 12~14 months. In this study, we detected the CD137L-expressing cells and IL-17-expressing cells in tumor tissues resected from patients with GBM. Expression of CD137L and IL-17 were assessed by immunohistochemistry, and the prognostic value of CD137L and IL-17 expression within the tumor tissues were assessed by Cox regression and Kaplan-Meier analysis. Immunohistochemical detection showed that positive cells of CD137L and IL-17 in glioblastoma tissue samples were 46.3% (19/ 41) and 73.2% (30/41) respectively. Expression of CD137L was not correlated with overall survival of GBM patients (P=0.594), while significantly longer survival rate was seen in patients with high expression of IL-17, compared to those with low expression of IL-17 (P=0.007). In addition, we also found that IL-17 expression was significantly correlated with Progression-free survival (PFS) (P=0.016) and death rate (P=0.01). Furthermore, multivariate Cox proportional hazard analyses revealed that IL-17 (P=0.018) and PFS (P=0.028) were independent factors affecting the overall survival probability. Kaplan-Meier analysis showed that PFS of high expression of IL-17 group were significantly longer (P=0.004) than low expression group with GBM. It is concluded that high levels of IL-17 expression in the tumor tissues may be a good prognostic marker for patients with GBM.Keywords
This publication has 26 references indexed in Scilit:
- Targeting brain cancer: advances in the molecular pathology of malignant glioma and medulloblastomaNature Reviews Cancer, 2010
- Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environmentsBlood, 2009
- Analysis of CD137 and CD137L Expression in Human Primary Tumor TissuesCroatian Medical Journal, 2008
- The promise of 4‐1BB (CD137)‐mediated immunomodulation and the immunotherapy of cancerImmunological Reviews, 2008
- Long-term survival with glioblastoma multiformeBrain, 2007
- LACK OF B7 EXPRESSION, NOT HUMAN LEUKOCYTE ANTIGEN EXPRESSION, FACILITATES IMMUNE EVASION BY HUMAN MALIGNANT GLIOMASNeurosurgery, 2007
- IL-17 Family Cytokines and the Expanding Diversity of Effector T Cell LineagesAnnual Review of Immunology, 2007
- [Expression of costimulator 4-1BBL and B7-1 on glioma cell lines].2006
- Human 4-1BB regulates CD28 co-stimulation to promote Th1 cell responsesEuropean Journal of Immunology, 1998
- Costimulation of CD28- T lymphocytes by 4-1BB ligand.The Journal of Immunology, 1997